This stock making HUGE waves 🌊

*Sponsored by FSD Pharma. Please see disclosures below.

Hey there, it’s me again. I wanted to share a cool biotech stock idea I’ve been tracking recently - FSD Pharma (Nasdaq: HUGE) – and why I’m excited about its prospects.

Recently, HUGE issued an announcement about a planned spin-off coming up.

This could have major implications for the stock at these levels. There is a very interesting story brewing right now. Make sure you stay up to date on it.

The biotech index was down around 2% on the year and starting to perk up, while the Nasdaq was up over 20% and showing signs of topping out.

In fact, my recent “Bullseye Trade” idea was a biotech stock, and the options I alerted to my members popped over 270% higher just a few days later.

Like I said, we’re on to something BIG right now… possibly even “HUGE” (Sorry, I know it is corny. Such a cool ticker I just have to use it a lot!)

I've been following this idea for some time, and I still think it’s worth keeping focus on.

And I think that right now we have a small window in time where we can see a massive move in some of the best biotech stocks as they play “catch up” to the bigger indexes.

The steady move higher we have seen in HUGE already is a great example of what I am talking about.

Here are the major points I think it is important to focus on when looking at FSD Pharma (Nasdaq: HUGE) right now…

The stock quietly moved up over 100% to start the year, then went through a consolidation phase for March and just started to break out of that Bull Flag.

So, the price action is pretty interesting… but I had to dig into WHY??

FSD Pharma (Nasdaq: HUGE) is an innovative biotech company that is best known for a drug candidate in Phase 1 testing that they hope will treat multiple sclerosis.

That is great, but I really felt there had to be something else brewing here.

As I started to dig deeper and put the pieces together, I stumbled on something that could be revolutionary.

It all started with a press release I read a few weeks ago where they announced that Gerry David was being added to the Board of Advisors.

Now, that might not mean a lot to most people, but I have known about Celsius Holdings (Nasdaq: CELH) for years now and traded options on the stock many, many times.

In case you don’t know, Gerry David was the Chief Executive Officer of CELH, where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic investors, and a rise in market capitalization that increased shareholder value 35-fold by exceeding $9 billion.

In the release, David said (emphases added), “I have seen countless products throughout my career, and I can honestly say that I have never seen anything as unique and disruptive as the product FSD Pharma is developing to counteract alcohol intoxication and misuse.”

When I read this, I thought, “Huh?” What is FSD Pharma (Nasdaq: HUGE) working on that would attract the attention of this beverage titan?

Going further down the rabbit hole, I read that a few weeks prior to that, Kevin Harrington was also added to the Advisory Board.

Guess who Gerry worked with as CELH exploded higher over those years?

Yep, Kevin & Gerry absolutely crushed it with their last beverage company in one of the all-time greatest …

Kevin Harrington is world-renowned as the inventor of the infomercial, pioneer of the “As Seen on TV” brand, and one of the original “Sharks” on the hit ABC show “Shark Tank.” He has launched more than 20 businesses that have each grown sales in excess of $100 million as part of a career that has introduced 1,000+ products generating over $6 billion in global sales. His business experience spans the globe, including opening distribution outlets in over 100 countries.

In the release Kevin said, “Throughout my career, my investments have the common thread of ground-floor opportunities in research and development of products that I believe can be transformational, whether it be a beverage, kitchen utensil, or, in the case of FSD Pharma (Nasdaq: HUGE), a strong pipeline of therapeutics, which include potential products that may provide significant help in alcohol misuse cases” (bold added).

Then, recently Kevin Harrington posted this Instagram video where he flat out tells everyone how excited he is to be working with FSD Pharma (Nasdaq: HUGE), and makes some bold claims about what he hopes to achieve.

Sure enough, when I looked back just a little further, I found a press release from FSD Pharma (Nasdaq: HUGE) talking about a new initiative to potentially reverse the negative effects of alcohol on brain function.

From the release…"FSD Pharma’s (Nasdaq: HUGE) existing pipelines and research priorities in brain and inflammatory disorders, including mental health, provides a natural extension to investigate the effects of alcohol on the brain. Our clinical and product development teams are exploring how to limit and potentially reverse the negative effects of alcohol on brain function," said Dr. Lakshmi Kotra (bold added).

When you connect all the dots, FSD Pharma (Nasdaq: HUGE) is putting together an all-star advisory team and actively developing something that could be a MASSIVE product.

I will keep a close eye on new developments, as we are clearly in the early stages here.

If all of this isn’t enough to get you amped up, then check out the technical indicators.

Let’s start with Barchart. You just can’t get any better than a perfect “100% buy” rating…

Then, look at TipRanks, which shows an equally impressive rating across all indicators…

We are checking all of the boxes when zooming over to Yahoo as well…

Great idea, great technicals… now, can they carry this across the finish line? 🏁

Take a look at the financials. FSD Pharma (Nasdaq: HUGE) is sitting on over $23 million as of their last filing, with negligible debt.

That is a book value over 50% of the current share price!

What are they going to do with all that cash besides develop new products?

Well, FSD Pharma (Nasdaq: HUGE) recently said its Board of Directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting shares over the next 12 months.

The 1.9 million shares figure represents about 5% of FSD’s issued and outstanding subordinate voting shares, the company said.

I don’t know about you, but I think I am really on to something with FSD Pharma (Nasdaq: HUGE)!

There is a potentially massive idea in the works… incredible technicals for the stock price… a stellar balance sheet for a tiny company… and even a share buyback in place!

As always, just because I love a stock doesn’t mean you shouldn’t do your own research. I’d suggest you visit their website, and learn more about the risks and potential rewards with the company.

Best of luck, and do your own due diligence as always!

To Your Success,

*Please see disclosures below